Literature DB >> 25562615

Oxytocin treatment prevents the cardiomyopathy observed in obese diabetic male db/db mice.

Eric Plante1, Ahmed Menaouar, Bogdan A Danalache, Denis Yip, Tom L Broderick, Jean-Louis Chiasson, Marek Jankowski, Jolanta Gutkowska.   

Abstract

Oxytocin (OT) is involved in the regulation of energy metabolism and in the activation of cardioprotective mechanisms. We evaluated whether chronic treatment with OT could prevent the metabolic and cardiac abnormalities associated with diabetes and obesity using the db/db mice model. Four-week-old male db/db mice and their lean nondiabetic littermates (db/+) serving as controls were treated with OT (125 ng/kg · h) or saline vehicle for a period of 12 weeks. Compared with db/+ mice, the saline-treated db/db mice developed obesity, hyperglycemia, and hyperinsulinemia. These mice also exhibited a deficient cardiac OT/natriuretic system and developed systolic and diastolic dysfunction resulting from cardiomyocyte hypertrophy, fibrosis, and apoptosis. These abnormalities were associated with increased reactive oxygen species (ROS) production, inflammation, and suppressed 5'-adenosine monophosphate kinase signaling pathway. The db/db mice displayed reduced serum levels of adiponectin and adipsin and elevated resistin. OT treatment increased circulating OT levels, significantly reduced serum resistin, body fat accumulation (19%; P<.001), fasting blood glucose levels by (23%; P<.001), and improved glucose tolerance and insulin sensitivity. OT also normalized cardiac OT receptors, atrial natriuretic peptide, and brain natriuretic peptide, expressions and prevented systolic and diastolic dysfunction as well as cardiomyocyte hypertrophy, fibrosis, and apoptosis. Furthermore, OT reduced cardiac oxidative stress and inflammation and normalized the 5'-adenosine monophosphate-activated protein kinase signaling pathway. The complete normalization of cardiac structure and function by OT treatment in db/db mice contrasted with only partial improvement of hyperglycemia and hyperinsulinemia. These results indicate that chronic treatment with OT partially improves glucose and fat metabolism and reverses abnormal cardiac structural remodeling, preventing cardiac dysfunction in db/db mice.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25562615     DOI: 10.1210/en.2014-1718

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  42 in total

1.  [Irbesartan ameliorates cardiac inflammation in type 2 diabetic db/db mice].

Authors:  Xian-Lang Ye; Wei-Chang Huang; Yan-Tao Zheng; Ying Liang; Wang-Qiu Gong; Chong-Miao Yang; Bin Liu
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2016-04-20

2.  Chronic oxytocin administration as a tool for investigation and treatment: A cross-disciplinary systematic review.

Authors:  Marilyn Horta; Kathryn Kaylor; David Feifel; Natalie C Ebner
Journal:  Neurosci Biobehav Rev       Date:  2019-10-21       Impact factor: 8.989

3.  Endogenous Oxytocin Levels in Relation to Food Intake, Menstrual Phase, and Age in Females.

Authors:  Anna Aulinas; Reitumetse L Pulumo; Elisa Asanza; Christopher J Mancuso; Meghan Slattery; Christiane Tolley; Franziska Plessow; Jennifer J Thomas; Kamryn T Eddy; Karen K Miller; Anne Klibanski; Madhusmita Misra; Elizabeth A Lawson
Journal:  J Clin Endocrinol Metab       Date:  2019-04-01       Impact factor: 5.958

4.  Chronic hindbrain administration of oxytocin is sufficient to elicit weight loss in diet-induced obese rats.

Authors:  Zachary S Roberts; Tami Wolden-Hanson; Miles E Matsen; Vitaly Ryu; Cheryl H Vaughan; James L Graham; Peter J Havel; Daniel W Chukri; Michael W Schwartz; Gregory J Morton; James E Blevins
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2017-07-26       Impact factor: 3.619

5.  On-Site Classification of Pansteatitis in Mozambique Tilapia (Oreochromis mossambicus) using a Portable Lipid-Based Analyzer.

Authors:  John A Bowden; Stephen E Somerville; Theresa M Cantu; Matthew P Guillette; Hannes Botha; Ashley S P Boggs; Wilmien Luus-Powell; Louis J Guillette
Journal:  Anal Methods       Date:  2016-05-16       Impact factor: 2.896

6.  Effects of Chronic Oxytocin Administration and Diet Composition on Oxytocin and Vasopressin 1a Receptor Binding in the Rat Brain.

Authors:  Sara M Freeman; Julie Ngo; Bhavdeep Singh; Megan Masnaghetti; Karen L Bales; James E Blevins
Journal:  Neuroscience       Date:  2018-07-31       Impact factor: 3.590

7.  Intranasal oxytocin reduces weight gain in diet-induced obese prairie voles.

Authors:  Adele M Seelke; Maya A Rhine; Konterri Khun; Amira N Shweyk; Alexandria M Scott; Jessica M Bond; James L Graham; Peter J Havel; Tami Wolden-Hanson; Karen L Bales; James E Blevins
Journal:  Physiol Behav       Date:  2018-08-23

8.  Chronic CNS oxytocin signaling preferentially induces fat loss in high-fat diet-fed rats by enhancing satiety responses and increasing lipid utilization.

Authors:  James E Blevins; Benjamin W Thompson; Vishwanath T Anekonda; Jacqueline M Ho; James L Graham; Zachary S Roberts; Bang H Hwang; Kayoko Ogimoto; Tami Wolden-Hanson; Jarrell Nelson; Karl J Kaiyala; Peter J Havel; Karen L Bales; Gregory J Morton; Michael W Schwartz; Denis G Baskin
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2016-01-20       Impact factor: 3.619

9.  Characterization of a mouse model of obesity-related fibrotic cardiomyopathy that recapitulates features of human heart failure with preserved ejection fraction.

Authors:  Linda Alex; Ilaria Russo; Volodymir Holoborodko; Nikolaos G Frangogiannis
Journal:  Am J Physiol Heart Circ Physiol       Date:  2018-07-13       Impact factor: 4.733

10.  Plasma Oxytocin Concentration in Pre- and Postmenopausal Women: Its Relationship with Obesity, Body Composition and Metabolic Variables.

Authors:  Sabrina Maestrini; Chiara Mele; Stefania Mai; Roberta Vietti; Annamaria Di Blasio; Luigi Castello; Daniela Surico; Gianluca Aimaretti; Massimo Scacchi; Paolo Marzullo
Journal:  Obes Facts       Date:  2018-10-30       Impact factor: 3.942

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.